Evidence map›Paper›PMID 42149705›Full record

ArticleThe Journal of endocrinology2026

Triiodothyronine-driven pro-inflammatory responses of dendritic cells are restrained by sphingolipid signaling.

Dana María Negretti-Borga, Mariana Pires Teixeira, Antonella Blanco, Elida Nahir Puentes, María Florencia Soler, Vanina Alejandra Alamino, Ana Carolina Donadio, Christopher James Clarke, María Del Mar Montesinos, Yusuf Awni Hannun and 1 more

Abstract read
In one paragraph

Article in The Journal of endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Dana María Negretti-BorgaCentro de Investigaciones en Bioquímica Clínica e Inmunología (CIBICI)- Consejo Nacional de Investigaciones Científicas y Tecnológicas (CONICET), Departamento de Bioquímica Clínica, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba (FCQ-UNC), Córdoba, Argentina.ORCID https://orcid.org/0000-0002-7283-9695
Mariana Pires TeixeiraCentro de Investigaciones en Bioquímica Clínica e Inmunología (CIBICI)- Consejo Nacional de Investigaciones Científicas y Tecnológicas (CONICET), Departamento de Bioquímica Clínica, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba (FCQ-UNC), Córdoba, Argentina.
Antonella BlancoCentro de Investigaciones en Bioquímica Clínica e Inmunología (CIBICI)- Consejo Nacional de Investigaciones Científicas y Tecnológicas (CONICET), Departamento de Bioquímica Clínica, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba (FCQ-UNC), Córdoba, Argentina.
Elida Nahir PuentesCentro de Investigaciones en Bioquímica Clínica e Inmunología (CIBICI)- Consejo Nacional de Investigaciones Científicas y Tecnológicas (CONICET), Departamento de Bioquímica Clínica, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba (FCQ-UNC), Córdoba, Argentina.
María Florencia SolerCentro de Investigaciones en Bioquímica Clínica e Inmunología (CIBICI)- Consejo Nacional de Investigaciones Científicas y Tecnológicas (CONICET), Departamento de Bioquímica Clínica, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba (FCQ-UNC), Córdoba, Argentina.
Vanina Alejandra AlaminoCentro de Excelencia en Productos y Procesos de Córdoba (CEPROCOR), Pabellón CEPROCOR, Santa María de Punilla, Córdoba, Argentina.
Ana Carolina DonadioCentro de Investigaciones en Bioquímica Clínica e Inmunología (CIBICI)- Consejo Nacional de Investigaciones Científicas y Tecnológicas (CONICET), Departamento de Bioquímica Clínica, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba (FCQ-UNC), Córdoba, Argentina.
Christopher James ClarkeStony Brook Cancer Center, Department of Medicine, Stony Brook University (SBU), Stony Brook, New York, USA.
María Del Mar MontesinosCentro de Investigaciones en Bioquímica Clínica e Inmunología (CIBICI)- Consejo Nacional de Investigaciones Científicas y Tecnológicas (CONICET), Departamento de Bioquímica Clínica, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba (FCQ-UNC), Córdoba, Argentina.
Yusuf Awni HannunStony Brook Cancer Center, Department of Medicine, Stony Brook University (SBU), Stony Brook, New York, USA.
Claudia Gabriela PellizasCentro de Investigaciones en Bioquímica Clínica e Inmunología (CIBICI)- Consejo Nacional de Investigaciones Científicas y Tecnológicas (CONICET), Departamento de Bioquímica Clínica, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba (FCQ-UNC), Córdoba, Argentina.ORCID https://orcid.org/0009-0002-8587-0760

Funding

Sphingolipids in Cancer Therapy and AngiogenesisP01CA097132 · NCI · STATE UNIVERSITY NEW YORK STONY BROOK · PI YUSUF AWNI HANNUN · 2003 to 2026
$30.8M
NCI NIH HHS P01 CA097132
6 · The paper itself

Abstract

We previously reported that triiodothyronine (T3) promotes maturation of dendritic cells (DCs) and enhances their ability to induce pro-inflammatory and cytotoxic T-cell responses through Akt signaling. However, the underlying mechanisms remain incompletely understood. Sphingosine-1-phosphate (S1P), a bioactive sphingolipid, is implicated under several pro-inflammatory conditions. Here, we investigated the role of sphingosine kinase 1 (SK1), S1P, and its receptors (S1PRs) in the immunomodulatory effects of T3 on DCs and the ensuing adaptive immune response. DCs were generated from the bone marrow of C57BL/6 wild-type or SK1 knockout mice and stimulated with T3 (T3-DC). To modulate the S1P pathway, PF-543 (SK1 inhibitor), S1P, or FTY720 (S1PR functional antagonist) was added prior to T3. Phosphorylated Akt (p-Akt) and phosphorylated STAT3 (p-STAT3) were analyzed by Western blotting. Splenocytes from BALB/c mice were co-cultured with DCs under SK1 or S1PR inhibition and exposed to T3. Cell markers and proliferation were evaluated by flow cytometry, and cytokines were measured by flow cytometry and ELISA. We show that the SK1/S1P/S1PR pathway regulates IL-12p70 production in T3-DC, while S1PRs also modulate IL-6 secretion. Mechanistically, S1P signaling mediates T3-induced Akt phosphorylation in DCs. STAT3 activation was observed in T3-DC and was not altered by inhibition of SK1 or S1PR. Although the SK1/S1P/S1PR axis did not alter T cell proliferation, S1PR inhibition increased IFN-γ, and inhibition of either SK1 or S1PRs enhanced IL-17 secretion by splenocytes. Altogether, these findings suggest that a complex sphingolipid-mediated signaling network modulates the immunostimulatory effects of T3 on DCs and the driven adaptive immunity.

Indexed as

Dendritic CellsInflammationLysophospholipidsSignal TransductionSphingolipidsSphingosineTriiodothyronineAnimalsCells, CulturedMiceMice, Inbred BALB CMice, Inbred C57BLMice, KnockoutPhosphotransferases (Alcohol Group Acceptor)Receptors, LysosphingolipidSphingosine KinaseLysophospholipidsPhosphotransferases (Alcohol Group Acceptor)Receptors, LysosphingolipidSphingolipidsSphingosinesphingosine 1-phosphateSphingosine KinaseSphk1 protein, mouseTriiodothyroninedendritic cell (DC)innate and adaptive immunitysphingolipidssphingosine-1-phosphate (S1P)triiodothyronine (T3)

Identifiers

PMID42149705
PMCPMC13281993

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.